BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

601 related articles for article (PubMed ID: 28727518)

  • 1. Therapeutic and Prognostic Implications of BRAF V600E in Pediatric Low-Grade Gliomas.
    Lassaletta A; Zapotocky M; Mistry M; Ramaswamy V; Honnorat M; Krishnatry R; Guerreiro Stucklin A; Zhukova N; Arnoldo A; Ryall S; Ling C; McKeown T; Loukides J; Cruz O; de Torres C; Ho CY; Packer RJ; Tatevossian R; Qaddoumi I; Harreld JH; Dalton JD; Mulcahy-Levy J; Foreman N; Karajannis MA; Wang S; Snuderl M; Nageswara Rao A; Giannini C; Kieran M; Ligon KL; Garre ML; Nozza P; Mascelli S; Raso A; Mueller S; Nicolaides T; Silva K; Perbet R; Vasiljevic A; Faure Conter C; Frappaz D; Leary S; Crane C; Chan A; Ng HK; Shi ZF; Mao Y; Finch E; Eisenstat D; Wilson B; Carret AS; Hauser P; Sumerauer D; Krskova L; Larouche V; Fleming A; Zelcer S; Jabado N; Rutka JT; Dirks P; Taylor MD; Chen S; Bartels U; Huang A; Ellison DW; Bouffet E; Hawkins C; Tabori U
    J Clin Oncol; 2017 Sep; 35(25):2934-2941. PubMed ID: 28727518
    [TBL] [Abstract][Full Text] [Related]  

  • 2. BRAF mutation and CDKN2A deletion define a clinically distinct subgroup of childhood secondary high-grade glioma.
    Mistry M; Zhukova N; Merico D; Rakopoulos P; Krishnatry R; Shago M; Stavropoulos J; Alon N; Pole JD; Ray PN; Navickiene V; Mangerel J; Remke M; Buczkowicz P; Ramaswamy V; Guerreiro Stucklin A; Li M; Young EJ; Zhang C; Castelo-Branco P; Bakry D; Laughlin S; Shlien A; Chan J; Ligon KL; Rutka JT; Dirks PB; Taylor MD; Greenberg M; Malkin D; Huang A; Bouffet E; Hawkins CE; Tabori U
    J Clin Oncol; 2015 Mar; 33(9):1015-22. PubMed ID: 25667294
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A clinicopathologic study of diencephalic pediatric low-grade gliomas with BRAF V600 mutation.
    Ho CY; Mobley BC; Gordish-Dressman H; VandenBussche CJ; Mason GE; Bornhorst M; Esbenshade AJ; Tehrani M; Orr BA; LaFrance DR; Devaney JM; Meltzer BW; Hofherr SE; Burger PC; Packer RJ; Rodriguez FJ
    Acta Neuropathol; 2015 Oct; 130(4):575-85. PubMed ID: 26264609
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pediatric low-grade gliomas can be molecularly stratified for risk.
    Yang RR; Aibaidula A; Wang WW; Chan AK; Shi ZF; Zhang ZY; Chan DTM; Poon WS; Liu XZ; Li WC; Zhang RQ; Li YX; Chung NY; Chen H; Wu J; Zhou L; Li KK; Ng HK
    Acta Neuropathol; 2018 Oct; 136(4):641-655. PubMed ID: 29948154
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interplay among BRAF, p16, p53, and MIB1 in pediatric low-grade gliomas.
    Horbinski C; Nikiforova MN; Hagenkord JM; Hamilton RL; Pollack IF
    Neuro Oncol; 2012 Jun; 14(6):777-89. PubMed ID: 22492957
    [TBL] [Abstract][Full Text] [Related]  

  • 6. BRAF V600E mutation and 9p21: CDKN2A/B and MTAP co-deletions - Markers in the clinical stratification of pediatric gliomas.
    Frazão L; do Carmo Martins M; Nunes VM; Pimentel J; Faria C; Miguéns J; Sagarribay A; Matos M; Salgado D; Nunes S; Mafra M; Roque L
    BMC Cancer; 2018 Dec; 18(1):1259. PubMed ID: 30558563
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Outcomes of BRAF V600E Pediatric Gliomas Treated With Targeted BRAF Inhibition.
    Nobre L; Zapotocky M; Ramaswamy V; Ryall S; Bennett J; Alderete D; Balaguer Guill J; Baroni L; Bartels U; Bavle A; Bornhorst M; Boue DR; Canete A; Chintagumpala M; Coven SL; Cruz O; Dahiya S; Dirks P; Dunkel IJ; Eisenstat D; Faure Conter C; Finch E; Finlay JL; Frappaz D; Garre ML; Gauvain K; Bechensteen AG; Hansford JR; Harting I; Hauser P; Hazrati LN; Huang A; Injac SG; Iurilli V; Karajannis M; Kaur G; Kyncl M; Krskova L; Laperriere N; Larouche V; Lassaletta A; Leary S; Lin F; Mascelli S; McKeown T; Milde T; Morales La Madrid A; Morana G; Morse H; Mushtaq N; Osorio DS; Packer R; Pavelka Z; Quiroga-Cantero E; Rutka J; Sabel M; Salgado D; Solano P; Sterba J; Su J; Sumerauer D; Taylor MD; Toledano H; Tsang DS; Valente Fernandes M; van Landeghem F; van Tilburg CM; Wilson B; Witt O; Zamecnik J; Bouffet E; Hawkins C; Tabori U
    JCO Precis Oncol; 2020; 4():. PubMed ID: 32923898
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Co-occurrence of histone H3 K27M and BRAF V600E mutations in paediatric midline grade I ganglioglioma.
    Pagès M; Beccaria K; Boddaert N; Saffroy R; Besnard A; Castel D; Fina F; Barets D; Barret E; Lacroix L; Bielle F; Andreiuolo F; Tauziède-Espariat A; Figarella-Branger D; Puget S; Grill J; Chrétien F; Varlet P
    Brain Pathol; 2018 Jan; 28(1):103-111. PubMed ID: 27984673
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Retrospective and integrative analyses of molecular characteristics and their specific imaging parameters in pediatric grade 1 gliomas.
    Coutant M; Lhermitte B; Guérin E; Chammas A; Reita D; Sebastia C; Douzal V; Gabor F; Salmon A; Chenard MP; Todeschi J; Coca A; Heng MA; Vincent F; Entz-Werlé N
    Pediatr Blood Cancer; 2022 Aug; 69(8):e29575. PubMed ID: 35373885
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Molecular genetics and therapeutic targets of pediatric low-grade gliomas.
    Tateishi K; Nakamura T; Yamamoto T
    Brain Tumor Pathol; 2019 Apr; 36(2):74-83. PubMed ID: 30929113
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Resection extent and BRAF V600E mutation status determine postoperative tumor growth velocity in pediatric low-grade glioma: results from a single-center cohort analysis.
    Gorodezki D; Zipfel J; Queudeville M; Sosa J; Holzer U; Kern J; Bevot A; Schittenhelm J; Nägele T; Ebinger M; Schuhmann MU
    J Neurooncol; 2022 Dec; 160(3):567-576. PubMed ID: 36319795
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Characterizing temporal genomic heterogeneity in pediatric low-grade gliomas.
    Lazow MA; Hoffman L; Schafer A; Osorio DS; Boué DR; Rush S; Wright E; Lane A; DeWire-Schottmiller MD; Smolarek T; Sipple J; Taggert H; Reuss J; Salloum R; Hummel TR; de Blank P; Pillay-Smiley N; Sutton ME; Asher A; Stevenson CB; Drissi R; Finlay JL; Fouladi M; Fuller C
    Acta Neuropathol Commun; 2020 Nov; 8(1):182. PubMed ID: 33153497
    [TBL] [Abstract][Full Text] [Related]  

  • 13. LOGGIC/FIREFLY-2: a phase 3, randomized trial of tovorafenib vs. chemotherapy in pediatric and young adult patients with newly diagnosed low-grade glioma harboring an activating RAF alteration.
    van Tilburg CM; Kilburn LB; Perreault S; Schmidt R; Azizi AA; Cruz-Martínez O; Zápotocký M; Scheinemann K; Meeteren AYNS; Sehested A; Opocher E; Driever PH; Avula S; Ziegler DS; Capper D; Koch A; Sahm F; Qiu J; Tsao LP; Blackman SC; Manley P; Milde T; Witt R; Jones DTW; Hargrave D; Witt O
    BMC Cancer; 2024 Jan; 24(1):147. PubMed ID: 38291372
    [TBL] [Abstract][Full Text] [Related]  

  • 14. BRAF Status in Personalizing Treatment Approaches for Pediatric Gliomas.
    Olow A; Mueller S; Yang X; Hashizume R; Meyerowitz J; Weiss W; Resnick AC; Waanders AJ; Stalpers LJ; Berger MS; Gupta N; James CD; Petritsch CK; Haas-Kogan DA
    Clin Cancer Res; 2016 Nov; 22(21):5312-5321. PubMed ID: 27217440
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical impact of combined epigenetic and molecular analysis of pediatric low-grade gliomas.
    Fukuoka K; Mamatjan Y; Tatevossian R; Zapotocky M; Ryall S; Stucklin AG; Bennett J; Nobre LF; Arnoldo A; Luu B; Wen J; Zhu K; Leon A; Torti D; Pugh TJ; Hazrati LN; Laperriere N; Drake J; Rutka JT; Dirks P; Kulkarni AV; Taylor MD; Bartels U; Huang A; Zadeh G; Aldape K; Ramaswamy V; Bouffet E; Snuderl M; Ellison D; Hawkins C; Tabori U
    Neuro Oncol; 2020 Oct; 22(10):1474-1483. PubMed ID: 32242226
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and Safety of Dabrafenib in Pediatric Patients with
    Hargrave DR; Bouffet E; Tabori U; Broniscer A; Cohen KJ; Hansford JR; Geoerger B; Hingorani P; Dunkel IJ; Russo MW; Tseng L; Dasgupta K; Gasal E; Whitlock JA; Kieran MW
    Clin Cancer Res; 2019 Dec; 25(24):7303-7311. PubMed ID: 31811016
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PD-L1 Expression in Pediatric Low-Grade Gliomas Is Independent of BRAF V600E Mutational Status.
    Martin AM; Bell WR; Yuan M; Harris L; Poore B; Arnold A; Engle EL; Asnaghi L; Lim M; Raabe EH; Eberhart CG
    J Neuropathol Exp Neurol; 2020 Jan; 79(1):74-85. PubMed ID: 31819973
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic Role of BRAF Mutation in Low-Grade Gliomas: Meta-analysis.
    Kai Z; Dingyang L; Zhuanyi Y
    World Neurosurg; 2021 Mar; 147():42-46. PubMed ID: 33316486
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Cell-Based MAPK Reporter Assay Reveals Synergistic MAPK Pathway Activity Suppression by MAPK Inhibitor Combination in
    Usta D; Sigaud R; Buhl JL; Selt F; Marquardt V; Pauck D; Jansen J; Pusch S; Ecker J; Hielscher T; Vollmer J; Sommerkamp AC; Rubner T; Hargrave D; van Tilburg CM; Pfister SM; Jones DTW; Remke M; Brummer T; Witt O; Milde T
    Mol Cancer Ther; 2020 Aug; 19(8):1736-1750. PubMed ID: 32451331
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MR Imaging of Pediatric Low-Grade Gliomas: Pretherapeutic Differentiation of
    Trasolini A; Erker C; Cheng S; Crowell C; McFadden K; Moineddin R; Sargent MA; Mata-Mbemba D
    AJNR Am J Neuroradiol; 2022 Aug; 43(8):1196-1201. PubMed ID: 35863783
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 31.